+44 (0)20 3910 4640 info@symmetron.net
  • 🗨 We’re hiring!
Symmetron
  • Services
  • Therapeutic areas
  • The Team
  • Careers
  • Contact
Select Page

Cost-Effectiveness of nintedanib in idiopathic pulmonary fibrosis in the U.S.

by Symmetron | Jan 18, 2019

Idiopathic Pulmonary Fibrosis Cost-Effectiveness of Nintedanib in Idiopathic Pulmonary Fibrosis in the U.S. Presented at AMCP NEXUS. October 22-25, 2018. Orlando, USA Authors Rinciog C, Bermingham S, Cornic L, Diamantopoulos A, Fan Y  Process \ Qualitative and...

Recent Comments

    Archives

    Categories

    Meta

    • Log in
    • Entries feed
    • Comments feed
    • WordPress.org
    • Privacy Policy
    © 2019 Symmetron Ltd